Roche Aktie

274,75 EUR -3,25 EUR -1,17 %

16:20:08

FSE

257,60 CHF -2,50 CHF -0,96 %

17:35:18

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.221,31 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

30.06.25Roche Holding AGChanges to the Roche Enlarged Corporate Executive Committee

23.06.25Roche Holding AGEarly data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A

20.06.25Roche Holding AGRoche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

WerbungRoche-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

16.06.25Roche Holding AGRoche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

16.06.25GlobeNewswireRoche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

15.06.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

15.06.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

04.06.25Roche Holding AGRoche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

04.06.25GlobeNewswireRoche’s Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

03.06.25GlobeNewswireRoche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

03.06.25Roche Holding AGRoche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

31.05.25GlobeNewswireNew data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

31.05.25Roche Holding AGNew data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

30.05.25Roche Holding AGRoche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

30.05.25GlobeNewswireRoche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

23.05.25GlobeNewswireCHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

23.05.25GlobeNewswireRoche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

23.05.25Roche Holding AGRoche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

23.05.25Roche Holding AGNew two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients

23.05.25GlobeNewswireNew two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients

22.05.25GlobeNewswireFDA approves Roche’s Susvimo for diabetic retinopathy

22.05.25Roche Holding AGFDA approves Roche’s Susvimo for diabetic retinopathy

20.05.25Roche Holding AGRoche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

20.05.25GlobeNewswireRoche provides update on FDA Advisory Committee meeting on Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

14.05.25Roche Holding AGRoche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis

14.05.25GlobeNewswireRoche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis

13.05.25Roche Holding AGTen-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

13.05.25GlobeNewswireTen-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer

12.05.25PR NewswireRoche announces $550 million investment to expand its Indianapolis diagnostics manufacturing hub

06.05.25Roche Holding AGRoche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

06.05.25GlobeNewswireRoche introduces innovative Elecsys PRO-C3 test to improve precision in evaluating liver fibrosis severity

30.04.25GlobeNewswireCHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

30.04.25Roche Holding AGCHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

29.04.25Roche Holding AGRoche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

29.04.25GlobeNewswireRoche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer

25.04.25Roche Holding AGNew England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission

25.04.25GlobeNewswireNew England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission

24.04.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

24.04.25GlobeNewswire[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche setzt Wachstumskurs mit Umsatzplus von 6% (CER) im ersten Quartal 2025 fort

24.04.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.